KEGG   DRUG: Glecaprevir and pibrentasvirHelp
Entry
D11014            Mixture   Drug                                   

Name
Glecaprevir and pibrentasvir;
Mavyret (TN)
Product
Component
(Glecaprevir [DR:D10814] | Glecaprevir hydrate [DR:D10815]), Pibrentasvir [DR:D10816]
Remark
Therapeutic category: 6250
ATC code: J05AP57
Product: D11014<JP/US>
Efficacy
Antiviral
  Disease
Chronic hepatitis C virus infection [DS:H00413]
Comment
Glecaprevir is an inhibitor and a substrate of P-gp, BCRP, OATP1B1/1B3.
Pibrentasvir is a substrate of P-gp; it is also an inhibitor of P-gp, BCRP and OATP1B1.
Metabolism
Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
Interaction
Transporter inhibition: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP57 Glecaprevir and pibrentasvir
      D11014  Glecaprevir and pibrentasvir <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D11014  Glecaprevir and pibrentasvir
Antiinfectives [br08350.html]
 Antivirals
  D11014
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11014
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11014
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11014
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11014
BRITE hierarchy
Other DBs
PubChem: 348350486
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system